These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36099542)

  • 21. CNS Demyelination with TNF-α Blockers.
    Kemanetzoglou E; Andreadou E
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):36. PubMed ID: 28337644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients.
    Kunimi K; Usui Y; Asakage M; Maehara C; Tsubota K; Mitsuhashi R; Umazume A; Kezuka T; Sakai JI; Goto H
    Ocul Immunol Inflamm; 2022 Jan; 30(1):223-230. PubMed ID: 32815752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy.
    Moll-Udina A; Miguel Escuder L; Hernanz I; Llorenç V; Fonollosa A; Cordero Coma M; Sainz de la Maza M; Espinosa G; González Guijarro JJ; Lopez Lopez F; Alba-Linero C; Hernández M; Martínez Costa L; Celdrán Vivancos D; Giralt L; Artaraz J; Soler Bartrina P; Jódar Márquez M; García de Vicuña R; Esquinas C; Adán A
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1591-1598. PubMed ID: 32657649
    [No Abstract]   [Full Text] [Related]  

  • 25. Adalimumab for the treatment of uveitis.
    LaMattina KC; Goldstein DA
    Expert Rev Clin Immunol; 2017 Mar; 13(3):181-188. PubMed ID: 28140700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial.
    Acharya NR; Ebert CD; Kelly NK; Porco TC; Ramanan AV; Arnold BF;
    Trials; 2020 Oct; 21(1):887. PubMed ID: 33109240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis.
    Kim MJ; Jones N; Steeples LR
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema.
    Lejoyeux R; Diwo E; Vallet H; Saadoun D; Tezenas du Montcel S; Bodaghi B; LeHoang P; Fardeau C
    Ocul Immunol Inflamm; 2018; 26(7):991-996. PubMed ID: 30096013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CNS demyelination with TNFα inhibitor exposure: A retrospective cohort study.
    Hutto SK; Rice DR; Mateen FJ
    J Neuroimmunol; 2021 Jul; 356():577587. PubMed ID: 33945946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
    Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab for the treatment of refractory noninfectious paediatric uveitis.
    Muñoz-Gallego A; Barral E; Enríquez E; Tejada P; Barceló A; de Inocencio J
    Int Ophthalmol; 2017 Jun; 37(3):719-725. PubMed ID: 27432171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
    Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
    Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.
    Lanz S; Seidel G; Skrabl-Baumgartner A
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):132. PubMed ID: 34419092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
    Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
    Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.
    Mercier AE; Ribeiro E; Korobelnik JF; Delyfer MN; Rougier MB
    Ocul Immunol Inflamm; 2018; 26(3):477-484. PubMed ID: 27775458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis-Related Uveitis in Patients under Anti-TNF-alpha Therapy: A Case Series.
    Hernanz I; Miguel Escuder L; Chamorro L; Moll-Udina A; Espinosa G; Sainz de la Maza M; Llorenç V; Adán A
    Ocul Immunol Inflamm; 2022 May; 30(4):839-844. PubMed ID: 33216652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials.
    Merrill PT; Vitale A; Zierhut M; Goto H; Kron M; Song AP; Pathai S; Fortin E
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1569-1575. PubMed ID: 32469621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.